Recursion's CFO Sold Stock at $3.08. What Does He Know That We Don't?

Think of a 10b5-1 plan like setting your fantasy football lineup on Wednesday: you can't be accused of reacting to Sunday's injury report because you locked it in early. It's a legitimate tool, and plenty of insiders use it.

But here's what makes people squirm: the plan was adopted on September 30, 2025, when the stock was trading significantly higher. Taylor essentially set up a system to sell shares on a schedule, and that schedule has been triggering sales as the stock craters. He still holds over 1.19 million shares after the latest sale, so he's not exactly abandoning ship. But the optics of your CFO selling near the floor, right before earnings? Not great.

The Platform-to-Product Problem

Recursion's big pitch has always been its AI drug discovery platform. The company merged with Exscientia in November 2024, creating what management calls one of the largest AI-based clinical pipelines in the industry. They've got partnerships with Roche, Sanofi, Bayer, and others, with over $20 billion in potential milestone payments across those deals.

That sounds incredible on paper. But milestones are like frequent flyer miles: they only matter if you actually earn them. Recursion's revenue tells a different story. In Q3 2025, the company brought in just $5.2 million in revenue, down over 80% from the prior year. The cash pile sat at $533 million, enough to fund operations through late 2027, but the company burned through $390 million in the trailing period.

The promise of AI drug discovery is essentially this: what normally takes 4-5 years, Recursion says it can do in 18 months using its "Virtual Cell" platform. That's a bold claim, and the industry is still waiting for proof. No AI-discovered drug has crossed the FDA finish line yet. Recursion has six active programs, four in oncology, two in rare diseases, and expects ten clinical readouts over the next year and a half.

That's a lot of at-bats. But you still need hits.

What Tuesday Could Reveal

When Recursion reports Q4 earnings on February 25, the headline number will probably be ugly. The consensus expects a $0.28 per-share loss, and if history is any guide, the company could miss even that. Last year's Q4 report saw Recursion post a loss of $0.53 per share against expectations of around $0.44, with revenue of just $4.6 million, well below the $19 million some analysts had penciled in.

Revenue at Recursion is lumpy by nature. It's driven by partnership milestones, not steady product sales. So a bad quarter doesn't necessarily mean the sky is falling. But when your stock has lost 66% of its value over the past year, investors aren't in a forgiving mood.

The real things to watch on Tuesday aren't the financials; they're the pipeline updates. Where does REC-4881, the company's lead cancer candidate, stand heading into FDA discussions expected in the first half of 2026? How is the Exscientia integration going? CEO Chris Gibson said at the JP Morgan Healthcare Conference that combining the two platforms would "dramatically reduce the amount that we're outsourcing" to contract research organizations. Has that actually happened?

The Bigger Picture

Recursion is a test case for the entire AI drug discovery thesis. The idea that machine learning can fundamentally reinvent how we find new medicines is one of the most exciting promises in biotech. But promises don't treat patients.

Right now, the market is telling Recursion that the story isn't enough anymore. NVIDIA left. Novo Holdings left. The CFO is selling on a schedule. And the stock is trading at prices that would've seemed unthinkable when the AI hype cycle was at full blast.

Tuesday's earnings call won't make or break Recursion. But it might tell us whether the company is getting closer to proving its platform actually works, or whether it's just an expensive science experiment running out of believers.

For a company built on the promise of artificial intelligence, the most human question remains: do the people closest to this story still believe in it?

Roche's New Breast Cancer Pill Has a Secret Weapon

Roche's oral breast cancer drug giredestrant just got its FDA date, and its secret weapon isn't the drug itself. It's the combination strategy that cut disease progression by 62% in the patients who need it most.